Surge after the surge: Anticipating the increased volume and needs of patients with head and neck cancer after the peak in <scp>COVID</scp>‐19

Bowman, Ryan; Crosby, Dana L.; Sharma, Arun

doi:10.1002/hed.26260

Cited by 17 publications

(25 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has been literature offering consensus-based recommendations, survey findings, or opinion regarding the appropriate triage of patients with head and neck cancer. Bowman et al 20 predicted a surge in patients with head and neck cancer after COVID-19 recovery. They cited concerns of contracting the virus, limitations of testing, and local and state restrictions as reasons new cancer patients would delay seeking care.…”

Section: Discussionmentioning

confidence: 99%

Impact of the Novel Coronavirus 2019 (COVID‐19) Pandemic on Head and Neck Cancer Care

Thompson

Lubek

Joy

et al. 2021

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Objective The study aimed to assess the impact of the coronavirus disease 2019 (COVID-19) pandemic on head and neck oncologic care at a tertiary care facility. Study Design This was a cross-sectional study conducted between March 18, 2020, and May 20, 2020. The primary planned outcome was the rate of treatment modifications during the study period. Secondary outcome measures were tumor conference volume, operative volume, and outpatient patient procedure and clinic volumes. Setting This single-center study was conducted at a tertiary care academic hospital in a large metropolitan area. Methods The study included a consecutive sample of adult subjects who were presented at a head and neck interdepartmental tumor conference during the study period. Patients were compared to historical controls based on review of operative data, outpatient procedures, and clinic volumes. Results In total, 117 patients were presented during the review period in 2020, compared to 69 in 2019. There was an 8.4% treatment modification rate among cases presented at the tumor conference. There was a 61.3% (347 from 898) reduction in outpatient clinic visits and a 63.4% (84 from 230) reduction in procedural volume compared to the prior year. Similarly, the operative volume decreased by 27.0% (224 from 307) compared to the previous year. Conclusion Restrictions related to the COVID-19 pandemic resulted in limited treatment modifications. Transition to virtual tumor board format observed an increase in case presentations. While there were reductions in operative volume, there was a larger proportion of surgical cases for malignancy, reflecting the prioritization of oncologic care during the pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of the Novel Coronavirus 2019 (COVID‐19) Pandemic on Head and Neck Cancer Care

Thompson

Lubek

Joy

et al. 2021

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“… 2 , 29 It is recommended that flexible fiberoptic intubation be avoided whenever possible. 30 Additionally, excessive bag-mask ventilation should be avoided due to the risk of dispersion of exhaled air. Furthermore, jet ventilation is considered particularly high risk and should be avoided if possible.…”

Section: Discussionmentioning

confidence: 99%

Coronavirus Disease-19

Baird

Sung

2020

Otolaryngologic Clinics of North America

View full text Add to dashboard Cite

This review explores the changes to practice associated with COVID-19 for providers treating patients with head and neck cancer and laryngeal pathology. The aim of the review is to highlight some of the challenges and considerations associated with treating this patient population during the pandemic. Additionally, it seeks to discuss some of the areas of concern related to ramping up clinical volume.

show abstract

“…7 As cancer pathways start to reopen, it is anticipated that those who did not seek help due to fears of burdening health services or catching this novel coronavirus in hospitals will present at a more advanced stage than they may have otherwise. 8 A strategic push for early diagnosis in cancer will almost inevitably have been hampered by these factors.…”

Section: Covid-19 and Clinical And Academic Cellular Pathologymentioning

confidence: 99%

Digital pathology and artificial intelligence will be key to supporting clinical and academic cellular pathology through COVID-19 and future crises: the PathLAKE consortium perspective

et al. 2020

View full text Add to dashboard Cite

The measures to control the COVID-19 outbreak will likely remain a feature of our working lives until a suitable vaccine or treatment is found. The pandemic has had a substantial impact on clinical services, including cancer pathways. Pathologists are working remotely in many circumstances to protect themselves, colleagues, family members and the delivery of clinical services. The effects of COVID-19 on research and clinical trials have also been significant with changes to protocols, suspensions of studies and redeployment of resources to COVID-19. In this article, we explore the specific impact of COVID-19 on clinical and academic pathology and explore how digital pathology and artificial intelligence can play a key role to safeguarding clinical services and pathology-based research in the current climate and in the future.

show abstract

Surge after the surge: Anticipating the increased volume and needs of patients with head and neck cancer after the peak in COVID‐19

Cited by 17 publications

References 15 publications

Impact of the Novel Coronavirus 2019 (COVID‐19) Pandemic on Head and Neck Cancer Care

Impact of the Novel Coronavirus 2019 (COVID‐19) Pandemic on Head and Neck Cancer Care

Coronavirus Disease-19

Digital pathology and artificial intelligence will be key to supporting clinical and academic cellular pathology through COVID-19 and future crises: the PathLAKE consortium perspective

Contact Info

Product

Resources

About